Vandetanib + Capecitabine + Oxaliplatin + Bevacizumab
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anal, Colon, and Rectal Cancers
Conditions
Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
Trial Timeline
Jul 1, 2006 → May 1, 2010
NCT ID
NCT00532909About Vandetanib + Capecitabine + Oxaliplatin + Bevacizumab
Vandetanib + Capecitabine + Oxaliplatin + Bevacizumab is a phase 1 stage product being developed by AstraZeneca for Anal, Colon, and Rectal Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT00532909. Target conditions include Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer.
What happened to similar drugs?
6 of 12 similar drugs in Anal, Colon, and Rectal Cancers were approved
Approved (6) Terminated (0) Active (6)
🔄HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00532909 | Phase 1 | Completed |
Competing Products
20 competing products in Anal, Colon, and Rectal Cancers